Nevada governor signs revised price transparency bill

Nevada Gov. Brian Sandoval (R) signed into law S.B. 539, which will require manufacturers of certain diabetes drugs and PBMs to make public information regarding their marketing practices. The bill will also require Nevada’s Department of Health and Human Services (DHHS) to compile a list of “essential” prescription diabetes drugs that will be subject to the transparency provisions. S.B. 539 is a revised version of S.B. 265, which Sandoval vetoed earlier this month. Nevada Sen. Michael Roberson (R) sponsored S.B. 539 (see BioCentury Extra, June 5).

S.B. 265, sponsored by Nevada Sen. Yvanna Cancela (D), would have required manufacturers of certain diabetes drugs to notify the state's DHHS 90 days before planned price increases. The bill also would not have required PBMs to publicize marketing practices. The new bill dropped the 90-day notice provision, but expanded the transparency measures to include PBMs...